Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging
The presence of activated macrophages (M∅) is an early and consistent marker of the inflammatory nature of atherosclerotic disease. Dextran-coated superparamagnetic iron oxide particles (SPIO) are avidly endocytosed. These particles have a strong effect on magnetic resonance signal and have been pro...
Gespeichert in:
Veröffentlicht in: | Atherosclerosis 2005, Vol.178 (1), p.67-73 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The presence of activated macrophages (M∅) is an early and consistent marker of the inflammatory nature of atherosclerotic disease. Dextran-coated superparamagnetic iron oxide particles (SPIO) are avidly endocytosed. These particles have a strong effect on magnetic resonance signal and have been proposed as a non-invasive probe for the presence of early non-occlusive atherosclerotic disease. We describe the extent to which endogenous and exogenous factors regulate M∅ uptake of SPIO particles.
Cultured murine M∅-like cells (J744A.1) incubated with SPIO (0, 11.2, 112.0 and 1120
μg
Fe/ml) demonstrated significantly reduced SPIO uptake when pretreated with lovastatin to 61% (
P < 0.001) and 43% (
P = 0.02) of control at 1.0
μM and 17.5
μM lovastatin respectively. Interferon-gamma (IFN-γ, 1000
U/ml) increased SPIO uptake to 163% of control,
P < 0.05. Interleukin-4 (IL-4, 40
ng/ml) also increased uptake (178% of control,
P < 0.04). In cells incubated with SPIO in the absence of serum proteins, SPIO uptake fell to 57% of control (
P < 0.001).
Uptake of SPIO by activated M∅ is regulated by endogenous cytokines and serum components as well and exogenous lovastatin. Thus, MRI signal changes after SPIO administration may reflect M∅ phagocytic capacity as well as M∅ presence. |
---|---|
ISSN: | 0021-9150 1879-1484 |
DOI: | 10.1016/j.atherosclerosis.2004.08.017 |